12 partner institutions
61 Principal Investigators
€ 120 million
funding for 5 years
About Oncode Institute
Over the past decades, the scientific and medical community has made tremendous progress in understanding and treating cancer. However, the disease still has a large burden on society as cancer has become the primary cause of death in The Netherlands. In an effort to address this unmet clinical need, Dutch cancer researchers have joined forces within Oncode Institute. To come up with new avenues for treatment and diagnosis, Oncode focuses on better understanding the fundamental mechanisms of cancer biology. With the ultimate goal to improve long-term survival and the quality of life of patients.Oncode serves as a platform for excellent cancer researchers in The Netherlands to collaborate, share knowledge, expertise and technology. As a virtual Institute it stimulates scientific freedom and offers dedicated support to optimize the translation of fundamental insights into clinical applications. Outsmarting cancer, impacting lives. Visit the Oncode website for more information about the project.
Over 800+ Oncode researchers working under a single strategy that focuses on six different research themes:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilising immune defence
Oncode invests heavily in the transfer of results from fundamental research into clinical applications. A team of dedicated specialists will help Oncode researchers with valorization of their findings. Furthermore, Oncode offers tailored training programs for affiliated researchers and actively invests in diversity through its Young Female Investigator program.
Accelerating innovation by partnership management
Based on its broad experience with partnership management and communication, Lygature has become a partner of Oncode. Lygature supports Oncode Institute with the following services:
- Program management
- Communication & external affairs
- Finance & IT-infrastructure
- Patient engagement
Lygature together with
Medications specifically for Children with Cancer
Separate research is needed in the case of children with cancer. Children differ from adults in the types of cancer they develop. Researchers at the recently opened Princess Máxima Centre for Pediatric Oncology are looking for medications that work more specific than chemotherapy. NEMO Kennislink visited them.
First Start-up Oncode Institute launched
Oncode Investigator, Alexander van Oudenaarden, is one of the pioneers in the field of single-cell sequencing. From his lab at the Hubrecht Institute the company Single Cell Discoveries was recently launched with the help of the valorization team of Oncode. This will make single-cell sequencing available for the broader research community.
Fundamental Science: an uncertain endeavour into uncharted territory
The majority of high impact medicines originate from curiosity driven research, American scientists found recently. Ton Rijnders and Madelon Maurice shed light on the importance of fundamental research, it's potential to reach into unchartered territory and yield surprising results, and the role Oncode hopes to play in the process